Economic evaluation of meningococcal vaccines: considerations for the future

Hannah Christensen (), Hareth Al-Janabi, Pierre Levy, Maarten J. Postma, David E. Bloom, Paolo Landa, Oliver Damm, David M. Salisbury, Javier Diez-Domingo, Adrian K. Towse, Paula Lorgelly, Koonal Shah (), Karla Hernandez-Villafuerte, Vinny Smith (), Linda Glennie, Claire Wright, Laura York and Raymond Farkouh
Additional contact information
Hannah Christensen: University of Bristol
Hareth Al-Janabi: University of Birmingham
Pierre Levy: Université Paris-Dauphine, PSL Research University, LEDa [LEGOS]
Maarten J. Postma: University Medical Center/University of Groningen
David E. Bloom: Harvard University
Paolo Landa: University of Exeter
Oliver Damm: Bielefeld University
David M. Salisbury: Centre on Global Health Security, Royal Institute of International Affairs
Javier Diez-Domingo: FISABIO-Public Health
Adrian K. Towse: Office of Health Economics
Karla Hernandez-Villafuerte: Office of Health Economics
Vinny Smith: Meningitis Research Foundation
Linda Glennie: Meningitis Research Foundation
Claire Wright: Meningitis Research Foundation
Laura York: Vaccine Medical Development, Scientific and Clinical Affairs, Pfizer Inc
Raymond Farkouh: Pfizer Inc

The European Journal of Health Economics, 2020, vol. 21, issue 2, No 12, 297-309

Abstract: Abstract In 2018, a panel of health economics and meningococcal disease experts convened to review methodologies, frameworks, and decision-making processes for economic evaluations of vaccines, with a focus on evaluation of vaccines targeting invasive meningococcal disease (IMD). The panel discussed vaccine evaluation methods across countries; IMD prevention benefits that are well quantified using current methods, not well quantified, or missing in current cost-effectiveness methodologies; and development of recommendations for future evaluation methods. Consensus was reached on a number of points and further consideration was deemed necessary for some topics. Experts agreed that the unpredictability of IMD complicates an accurate evaluation of meningococcal vaccine benefits and that vaccine cost-effectiveness evaluations should encompass indirect benefits, both for meningococcal vaccines and vaccines in general. In addition, the panel agreed that transparency in the vaccine decision-making process is beneficial and should be implemented when possible. Further discussion is required to ascertain: how enhancing consistency of frameworks for evaluating outcomes of vaccine introduction can be improved; reviews of existing tools used to capture quality of life; how indirect costs are considered within models; and whether and how the weighting of quality-adjusted life-years (QALY), application of QALY adjustment factors, or use of altered cost-effectiveness thresholds should be used in the economic evaluation of vaccines.

Keywords: Meningitis; Meningococcal; Vaccine; Cost-effectiveness; QALY (search for similar items in EconPapers)
JEL-codes: I (search for similar items in EconPapers)
Date: 2020
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s10198-019-01129-z Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
Working Paper: Economic evaluation of meningococcal vaccines: considerations for the future (2020)
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:eujhec:v:21:y:2020:i:2:d:10.1007_s10198-019-01129-z

Ordering information: This journal article can be ordered from
http://www.springer. ... cs/journal/10198/PS2

DOI: 10.1007/s10198-019-01129-z

Access Statistics for this article

The European Journal of Health Economics is currently edited by J.-M.G.v.d. Schulenburg

More articles in The European Journal of Health Economics from Springer, Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ) Contact information at EDIRC.
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().